Antheia
1 known investors
Antheia manufactures biosynthetic active pharmaceutical ingredients and key starting materials for essential medicines using advanced fermentation-based biosynthesis, replacing traditional agricultural sourcing to improve pharmaceutical supply chain reliability. The company serves pharmaceutical manufacturers and drug developers seeking more efficient, sustainable, and consistent sources for complex medicine ingredients.
Advanced ManufacturingBiotechMedical Devices
Investors · 1
In the news
- Antheia seals 2nd series C funding close, hitting more than $175M in a yearfiercepharma.com · 2026
- Antheia Raises $24M in Second Close of Series C Financingfinsmes.com · 2026
- Antheia Raises Additional $24 Million to Complete Series C Financing, Bringing Total Funds Raised to More than $175 Million Over Past Yearprnewswire.com · 2026
- Antheia Raises $56M in Series C Fundingfinsmes.com · 2025
- Medpathtrial.medpath.com · 2025
- Antheia Raises $56 Million in Series C Financing to Fuel Global Commercialization Strategy - Antheiaantheia.bio · 2025